article
Fast-tracking the approach to drug discovery and development
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
List view / Grid view
Pfizer
news
Pfizer expands clinical research unit in Belgium
Pfizer currently undertakes studies on healthy volunteers on two floors of the existing Erasme One-Day Hospital in the Brussels region, Belgium. To increase capacity, Pfizer’s original office and volunteers screening area has been divided into two separate units: one office and screening area outside the hospital for ambulatory visits, and…
news
Big pharma establishes new industry standards group
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
article
Draper and Pfizer partner on human organ-on-a-chip technology
The companies will collaborate to create unique versions of Draper’s Microphysiological Systems (MPS) technology, with the aim of creating more effective disease models...
news
Painkiller celecoxib slows cancer growth rate
26 May 2016 | By Victoria White, Digital Content Producer
Scientists have found that a widely prescribed painkiller, celecoxib, slows the growth rate of a specific kind of cancer in animal models...
news
Pfizer awards more than $1 million to fund metastatic breast cancer research
11 May 2016 | By Victoria White, Digital Content Producer
Pfizer has awarded a total of more than $1 million in funding to five leading advocacy organisations to support metastatic breast cancer scientific research...
news
Allergan and Pfizer terminate merger agreement
6 April 2016 | By Victoria White
The decision was driven by the actions announced by the US Department of Treasury to reform inversion tax rules, which the companies concluded qualified as an “Adverse Tax Law Change”. Market rumour suggests that Pfizer will now target Shire or AstraZeneca and shares in both companies went up with the…
news
Pfizer joins the Human Vaccines Project
22 March 2016 | By Victoria White
The Human Vaccines Project is focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection...
news
Breast Cancer Now Catalyst Programme aims to stop breast cancer
9 February 2016 | By Victoria White
The programme aims to bring together breast cancer researchers and pharmaceutical companies to pool resources and stop women dying from breast cancer by 2050...
news
Pfizer to give a keynote address on reviving covalent drug design in oncology at SMi’s 15th annual event this February
29 January 2016 | By SMi Group
SMi group reports: Doug Johnson, Research Fellow at Pfizer will be giving a keynote address on Day 1 at the SMi’s 15th annual Advances and Progress in Drug Design conference...
news
ADDoPT project set to transform the UK pharma industry
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
news
Calibr and Pfizer to develop heart failure therapies
14 January 2016 | By Victoria White
Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists...
news
Pfizer expands its R&D investment strategy
12 January 2016 | By Victoria White
The first four investments of the newly focused initiative include $46 million in financing to companies at early stages of the discovery process that are actively exploring Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy...
news
BioAtla and Pfizer in CAB antibody collaboration
8 December 2015 | By Victoria White
BioAtla and Pfizer will each have a license to the other's respective technology to pursue the development and commercialisation of several CAB-ADC antibodies...
news
Heptares and Pfizer to focus on GPCR targets
30 November 2015 | By Victoria White
Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...